Benzinga's Weekend M&A Chatter

The following are the M&A deals, rumors and chatter circulating on Wall Street for Friday June 3 through Sunday June 5, 2016: Twitter, Yahoo Said to have Discussed Potential Merger The Rumor:
Twitter TWTR met with Yahoo YHOO management, including CEO Marissa Mayer, to discuss a potential merger, according to sources as reported by the NY Post on Friday. The meeting is said to have taken place several weeks ago, but Twitter decided to not to proceed with the bidding process. Yahoo and Twitter declined comment. Verizon VZ is still seen as the front runner to acquire Yahoo's core internet business, with AT&T T and Dan Gilber also potential buyers. Yahoo fell 15% Friday to close at $36.60. McKesson Considering Separation of IT Unit The Rumor:
McKesson Corp. MCK is considering separation its information-technology business, according to sources as reported by the Wall Street Journal late Thursday. The unit is said to be valued at more than $5 billion. McKesson closed at $186.46 on Friday, down $1.33. AstraZeneca, Teva, Biogen, Allergan Said to be Potential Bidders for Acadia The Rumor:
AstraZeneca AZN is said to be among potential bidders for Acadia Pharmaceuticals, according to a report from the UK Daily Mail late Friday. Sources say Acadia investors would not accept less than $60 per share. Other potential buyers include Teva Pharmaceutical Industries TEVA, Biogen BIIB and Allergan AGN, the report said. Acadia closed at $36.07 on Friday and traded up 3.5% after-hours. Bayer Chairman Said to have Held Secret Meeting With Investors Regarding Monsanto Bid The Rumor:
Monsanto MON shares spiked higher Friday, on a tweet from Fox Business' Charlie Gasparino indicating that the Bayer BAYRY Chariman Werner Baumann held a secret meeting on Thursday, to discuss the bid to acquire the U.S. agricultural company. Sources who attended the meeting said Baumann is willing to increase the offer for Monsanto. Bayer offered $122 per share for Monanto last month, but shares have remained around $111 due in part to regulatory concerns and pressure from Bayer shareholders, who have been less than enthusiastic regarding the bid. Monsanto closed at $111.00 on Friday, up $0.64.